Adagene Inc
$ 1.78
-3.78%
26 Dec - close price
- Market Cap 84,836,000 USD
- Current Price $ 1.78
- High / Low $ 1.84 / 1.76
- Stock P/E N/A
- Book Value 0.80
- EPS -0.64
- Next Earning Report 2026-04-01
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.25 %
- ROE -0.63 %
- 52 Week High 3.16
- 52 Week Low 1.30
About
Adagene Inc. is a clinical-stage biopharmaceutical company based in Suzhou, China, specializing in the development of innovative monoclonal antibody therapies for oncology. Utilizing its proprietary technologies, the company is at the forefront of creating next-generation antibody drug candidates designed to enhance therapeutic efficacy while minimizing adverse effects in cancer treatment. With a promising pipeline of drug candidates that address significant unmet medical needs within the oncology space, Adagene is poised to make impactful contributions to the biopharmaceutical industry and improve outcomes for patients battling cancer.
Analyst Target Price
$9.51
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-12-03 | 2025-08-12 | 2025-05-28 | 2025-03-24 | 2024-11-27 | 2024-07-25 | 2024-05-29 | 2024-03-29 | 2023-11-29 | 2023-08-31 | 2023-05-31 | 2023-03-28 |
| Reported EPS | 0 | -0.23 | -0.17 | -0.29 | 0 | -0.285 | 0 | -0.27 | -0.42 | -1.48 | -0.38 | -1.55 |
| Estimated EPS | -0.18 | -0.33 | -0.17 | -0.47 | 0 | -0.26 | 0 | -0.27 | -0.42 | -0.93 | -0.38 | -0.4 |
| Surprise | 0.18 | 0.1 | 0 | 0.18 | 0 | -0.025 | 0 | 0 | 0 | -0.55 | 0 | -1.15 |
| Surprise Percentage | 100% | 30.303% | 0% | 38.2979% | None% | -9.6154% | None% | 0% | 0% | -59.1398% | 0% | -287.5% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-01 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.21 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ADAG
2025-12-18 16:09:10
Adagene Inc. (NASDAQ:ADAG) received Fast Track Designation from the FDA for its cancer therapy muzastotug in combination with Merck’s KEYTRUDA for treating adult patients with microsatellite stable metastatic colorectal cancer. This designation aims to accelerate the development and review of the drug, which has shown encouraging efficacy and a favorable safety profile. The company plans to release updated clinical data soon and is preparing for a registration trial in 2027.
2025-12-18 12:08:48
Lifesci Capital's C. Zhu projects Adagene (NASDAQ:ADAG) to report a loss of ($0.45) per share for FY2025, a more optimistic forecast than the consensus of ($0.60), and anticipates ($0.71) for FY2026, maintaining a "Strong-Buy" rating. The company currently holds a "Moderate Buy" consensus rating with an average price target of $7.67, despite shares trading near multi-month lows with limited institutional ownership.
2025-12-17 16:09:39
The FDA has granted Fast Track designation to Adagene's experimental cancer drug, muzastotug, for use in combination with Merck’s pembrolizumab for metastatic colorectal cancer. This designation aims to accelerate the drug's development and review, supported by promising clinical evidence. Adagene plans a registration trial in 2027, with Lucid Capital Markets initiating coverage with a Buy rating.
2025-12-17 16:08:56
Adagene (ADAG) has announced that its drug Muzastotug (ADG126) has received Fast Track Designation from the FDA. This designation aims to facilitate the development and expedite the review of new drugs to treat serious conditions and fill an unmet medical need. The article provides only a headline and no further details regarding the drug or its implications.
2025-12-17 16:08:45
Adagene Inc. (ADAG) announced that the FDA granted Fast Track designation to its lead clinical-stage immuno-oncology candidate, muzastotug (ADG126), in combination with Merck’s Keytruda for treating adult patients with microsatellite-stable metastatic colorectal cancer. This designation aims to facilitate drug development and expedite review for serious diseases with unmet medical needs. ADAG shares surged 13.8% following the announcement, reflecting positive investor sentiment.
2025-12-17 07:43:00
Adagene Inc. (ADAG) has received FDA Fast Track designation for its immuno-oncology candidate, muzastotug (ADG126), in combination with Merck’s Keytruda for microsatellite-stable metastatic colorectal cancer. This designation aims to expedite the development and review of therapies for serious conditions with unmet medical needs. Following the announcement, ADAG’s shares saw a significant increase.
